Articles tagged with Parkinsons Disease
A team of researchers from CRCHUM has identified a set of biomarkers in blood samples that could help diagnose Parkinson's disease. The study found that immune cells in the blood were activated and overexpressed genes associated with stress responses in patients with Parkinson's, forming a unique genetic signature.
A large-scale study from Karolinska Institutet reports that individuals with an autism diagnosis are four times more likely to develop early-onset Parkinson's disease. The researchers believe that shared underlying biological mechanisms may be at play, particularly involving the neurotransmitter dopamine.
Researchers discovered that specific neurons in the basal ganglia make precise decisions about when to allow and stop movements, licensing the timing of movement. This fine-grained movement control has important implications for understanding neurological disorders like Parkinson's disease.
Autophagy and lysosomal pathways orchestrate the unconventional secretion of PARK7, a PD-associated protein, in response to cellular stress. The study reveals a unique mechanism involving coordinated actions of macroautophagy and chaperone-mediated autophagy.
Davis Joseph's groundbreaking discovery identifies a common master switch that can cure multiple brain-related diseases with a single method. The unified theory establishes that regulating axon-based 4E-BP2 protein deamidation can control disease progression.
Researchers identified a dual learning system in the brain that enables habits to form and provides a scientific basis for breaking bad habits. The study suggests that replacing an action consistently can lead to the APE system forming a new habit, offering a potential strategy for overcoming addictions.
Researchers at Mass General Brigham have pinpointed a 'sweet spot' for focused ultrasound treatment to provide significant relief from essential tremor. The study identified a specific subregion of the brain's thalamus that can result in optimal and long-lasting tremor improvements while reducing side effects. With this breakthrough, p...
A team of researchers has discovered a small molecule that can selectively block cell death, which could lead to new treatments for neurodegenerative conditions. By targeting the killer protein BAX, the molecule can prevent excessive cell death in neurons, potentially slowing or halting disease progression.
A study found that exercise improves the maturation of transplanted stem cells and their integration with host neurons in a rodent model of Parkinson's disease. This enhancement is attributed to increased secretion of beneficial proteins in exercising rats, promoting transplant survival and function.
A new study reveals how a promising Parkinson's drug works by inhibiting the enzyme USP30, which prevents damaged mitochondria from being degraded. This breakthrough could lead to targeted therapies for Parkinson's disease and chronic kidney disease.
A team of researchers has shown that it may be possible to diagnose Parkinson's disease years before it becomes untreatable by scanning people's brains with fMRI. The study used ultra-high field experimental MRI scanners and analyzed brain activity in response to sensory impairments such as loss of smell and visual deficits.
A study published in Neurology found that eating more ultra processed foods may speed up early signs of Parkinson's disease. Participants who consumed over 11 servings of ultra-processed food per day had a higher likelihood of developing three or more early symptoms of the disease.
Researchers have found that promoting glucose metabolism in glial cells can relieve inflammation and photoreceptor degeneration in Alzheimer's patients. This discovery presents an exciting new therapeutic target for treating neurodegenerative conditions like Parkinson's.
Researchers at KAIST have identified a key mechanism behind neuroinflammatory responses in Parkinson's disease, which is regulated by an RNA editing enzyme called ADAR1. This discovery suggests that targeting this enzyme could serve as a novel therapeutic strategy for treating the disease.
Researchers from Université Laval discovered a non-invasive retinal exam can detect Parkinson's disease biomarkers, offering early diagnosis and potential intervention. The study found distinct retinal responses to light stimuli in people with Parkinson's compared to healthy individuals.
Researchers developed promising α-synuclein PET tracers that can visualize protein aggregates in living patients, enabling earlier diagnosis and treatment monitoring. Tracers like [18F]C05-05 and [18F]ACI-12589 showed significant results in distinguishing synucleinopathies from healthy controls.
Researchers at UCSF found clinically significant improvements in mood, cognition, and motor function after psilocybin therapy for patients with mild to moderate Parkinson's disease. The study suggests that psilocybin could provide relief from multiple symptoms of the disease by reducing inflammation and promoting neuroplasticity.
Researchers discovered that the brain suppresses the current action without using another mechanism to inhibit it, enabling seamless transitions between actions. This finding could lead to the development of biologically-inspired robotic systems and improve clinical treatments for Parkinson's patients.
A misfolded protein in spinal fluid facilitates reliable Parkinson's diagnosis even in its early stages. The biomarker has a sensitivity and specificity of over 90%, making it a promising tool for disease management and potential therapy development.
Researchers found that ATP regulates protein condensation and cytoplasm viscosity, preventing harmful protein aggregates. Boosting ATP production decreases viscosity, dispersing existing and preventing future protein aggregations.
A phase 1 clinical trial found that nerve cells derived from embryonic stem cells can produce dopamine, a chemical lacking in Parkinson's patients. The treatment has been licensed to BlueRock Therapeutics and is expected to proceed to a larger patient group in the first half of 2025.
Dr. Rhonda Winegar investigates the effectiveness of music therapy in supporting neurological care, including its ability to reduce anxiety and depression in Alzheimer's patients. Her research also highlights its potential to regulate heart rate and blood pressure, as well as improve motor function in individuals with Parkinson's disease.
A novel AI tool, RibbonFold, predicts the structures of amyloids, revealing previously overlooked nuances in their formation and evolution. This breakthrough may reshape how researchers approach neurodegenerative disease treatment and offers a scalable method for analyzing harmful protein aggregates.
Researchers will examine the link between cellular senescence and Parkinson's disease onset and progression. The team aims to find new ways to slow disease progression and establish senescence as a novel target for treatment.
A University of Florida researcher has developed a groundbreaking AI tool called VisionMD that analyzes videos of patients with Parkinson's disease and other movement disorders. The tool provides valuable information about how the disease is progressing and responding to medications, improving patient care and advancing clinical research.
Dr. J. Timothy Greenamyre is awarded the 2025 Jay Van Andel Award for his pioneering research into gene-environment interactions and its improved understanding of Parkinson's development and progression. The award highlights his work on mitochondria, LRRK2, and pesticide exposure risks in Parkinson's disease.
Researchers developed a simple, cost-effective blood test that detects Parkinson's disease long before symptoms emerge by analyzing transfer RNA fragments. The test has an accuracy surpassing existing clinical diagnostic tools and may alleviate uncertainty faced by patients and clinicians.
Researchers used CRISPR interference to examine every gene in the human genome and discovered a new set of genes contributing to Parkinson's disease risk. The study identified the Commander complex, which regulates lysosomal function and is implicated in PD risk, offering opportunities for new treatments.
A small protein involved in neurodegeneration leading to Parkinson's disease also drives a type of skin cancer known as melanoma, according to new research. The study suggests new avenues for drug development to reduce the risk of developing both diseases by targeting alpha-synuclein.
Researchers investigated the neuroregenerative potential of 5-NOT and Epi, discovering they protected SH-SY5Y cells from MPP+ toxicity by regulating key proteins. The findings support 5-NOT as a glycomimetic drug candidate for Parkinson's disease treatment.
A new study by the University of Turku found that up to one in six Parkinson's disease diagnoses are later corrected, with most changes occurring within two years. The study highlights the challenges of distinguishing Parkinson's disease from other similar disorders and emphasizes the need for improved diagnostic processes and training.
Researchers at Johns Hopkins Medicine have discovered how a group of proteins linked to Parkinson's and ALS act as 'guardians' of mitochondria, maintaining their normal size and function. The study found that when mitochondria become too large, they leak mitochondrial DNA into the cytosol, triggering an inflammatory response.
A new study found that a harmful build-up of the alpha-synuclein protein in nerve clusters near the heart may contribute to Parkinson's-related cardiac autonomic dysfunction. This suggests that targeting toxic protein clumps outside the brain could help manage symptoms and quality of life for people with Parkinson's.
Researchers at Temple University have discovered a new way to block the enzyme DLK, which plays a key role in neurodegenerative diseases. The breakthrough approach protects damaged neurons while preserving healthy neuron function.
A new study suggests AI-driven smart devices can revolutionize healthcare by detecting cardiac issues early, triggering emergency responses. The Internet of Medical Things (IoMT) technology enables real-time patient monitoring and analysis, improving efficiency and reducing costs.
Researchers at UT Health San Antonio are among the first to use adaptive deep brain stimulation technology that adjusts treatment based on a patient's symptoms. This innovative approach offers improved therapy and symptom optimization for patients with Parkinson's disease, dystonia, epilepsy, and essential tremor conditions.
Researchers have developed a new strategy to target hard-to-target proteins in human cells by reprogramming proteases to selectively degrade disease-causing proteins. The study demonstrates proof of concept for developing novel therapies for Parkinson's disease, cancers, and other illnesses, using α-Synuclein as a model protein.
Researchers developed an automated MRI processing and machine learning software to diagnose Parkinson’s disease, reducing diagnostic time by up to 96%. The software uses diffusion-weighted MRI and a noninvasive biomarker technique to identify neurodegeneration in the brain, providing more precise diagnoses.
Researchers at the WEHI have made a major breakthrough in understanding Parkinson's disease by determining the first ever structure of human PINK1 bound to mitochondria. This discovery paves the way for the development of new drugs to treat the condition, which currently has no cure or drug to stop its progression.
Researchers have discovered a blood test that can identify patients with a sleep disorder who are most likely to develop Dementia with Lewy Bodies. The blood test analyzes two proteins in the blood associated with Alzheimer's disease and predicted dementia risk in almost 90% of patients, four years before symptoms appeared.
The University of Texas at Arlington hosted the 74th Fort Worth Regional Science and Engineering Fair, attracting more students than ever. The fair featured original research projects on various topics, including using earthworms to remove toxic lead from soil and creating a robotic glove for people with Parkinson's disease.
Researchers discovered genetic variants in ITSN1 significantly increase Parkinson's disease risk, especially among rare mutations. The study highlights ITSN1 as a promising therapeutic target and underscores the value of large-scale genetic sequencing.
A Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease, in which a patient's stem cells are reprogrammed to replace dopamine cells. The trial uses autologous stem cell transplantation, avoiding immunosuppressive treatments, and has enrolled three patients so far.
A new study projects that Parkinson's disease cases will increase by 112% to 25.2 million worldwide by 2050, mainly due to population ageing. The largest number of cases is expected in East Asia, with the highest prevalence among people aged over 80.
The Aligning Science Across Parkinson’s (ASAP) initiative offers funding of up to $6M for research community members to develop sustainable tools for Parkinson’s disease research. The funding supports the development of preclinical models, detection reagents, and modulation agents to accelerate therapeutic research.
People with obstructive sleep apnea have an increased risk of developing Parkinson’s disease. Using continuous positive airway pressure (CPAP) within two years of a sleep apnea diagnosis may reduce this risk, according to a preliminary study.
La Jolla Institute scientists found that a protein in brain cells drives Parkinson's onset and may explain why the disease is more common in men. PINK1 appears to mark brain cells for immune cell attack, leading to inflammation and death.
The FDA has approved a new treatment for Parkinson's disease that can adjust to the individual's brain activity, providing precise stimulation. This technology, known as adaptive deep brain stimulation (aDBS), detects patterns of brain activity and delivers tailored electric pulses to reduce symptoms.
New study finds that limitations on working memory exist due to learning, rather than capacity, and shed light on dopamine-related disorders like Parkinson's, ADHD, and schizophrenia. By understanding this process, clinicians may adopt different treatment options for patients with these conditions.
Researchers from Osaka University found that peristaltic pump action promotes amyloid nucleation in supersaturated fluids, including blood and cerebrospinal fluid. High shear stress caused by the pumping motion mechanically breaks supersaturation to induce amyloid formation.
Researchers have discovered how cells turn on their recycling process and create 'garbage bags' to remove proteins, shedding new light on a crucial aspect of maintaining health. The study may lead to future treatments that can promote healthy ageing and target diseases like Parkinson's and Alzheimer's.
A global study analyzed brain images of over 2,500 people with Parkinson's disease to identify patterns of neurodegeneration and create metrics for each clinical stage. The research could lead to better diagnostic tools and enable new treatments to be tested and monitored.
McGill researchers found that music at an individual's natural tempo significantly reduces pain perceptions. The study discovered the greatest reductions in pain levels occurred when melodies were played at a rate matching the participant's own preferred tempo.
A new study led by UCL researchers has found that the GLP-1 drug exenatide has no positive impact on movement, symptoms, or brain imaging in people with Parkinson's disease. The trial involved 194 participants and ran for 96 weeks, with no benefits shown in any of these areas.
A Maynooth University study found that 84% of Parkinson's patients struggle with sleep issues, linked to depression, independent living difficulties and a decline in quality of life. Sleep problems worsen the severity of 'OFF periods' and are a significant burden on quality of life.
Researchers used AI to identify genetic factors in Parkinson's disease progression and FDA-approved drugs that can be repurposed for treatment. The study found potential risk genes like SNCA and LRRK2, which are known to cause inflammation, and identified candidate drugs such as simvastatin.
Researchers found that biotin supplementation reverses neurotoxicity in human nerve cells, improving mitochondrial function and reducing cell loss. Biotin metabolism was identified as a modifier of manganese-induced neurodegeneration, offering potential therapeutic strategy for Parkinson's disease
Researchers have found that microglia function differently in adult male versus female mice when given an enzyme inhibitor, with potential broad implications for how neurological diseases are studied. This discovery highlights the necessity of gender-specific research and may lead to new disease-modifying therapies targeting microglia.
Researchers developed a nanoparticle-based wireless DBS system that restores dopaminergic neurons in Parkinson's disease models. The system uses near-infrared laser technology to activate thermosensitive TRPV1 receptors, clearing α-syn aggregates and improving motor function.
The NIH is leading the implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson’s Act, which aims to coordinate research and services across federal agencies, speed treatment development, and improve early diagnosis for Parkinson’s disease and related neurodegenerative disorders.